

Remarks/Arguments

As requested by the Examiner, the Applicant hereby submits a substitute copy of the Sequence listing in compliance with the requirements of 37 CFR 1.822 and/or 1.823. In addition, the Applicant confirms that the sequence listing information recorded in the computer readable form is identical to the written sequence listing and includes no new matter.

The Examiner indicates that the amendment submitted on January 7, 2003 related to the drawings, as well as to DNA and amino acid sequences has not been entered because the location of each change must be specified individually and unambiguously. The Applicant believes the amendments related to the drawings complied with the rules in force at the time of their initial filing, i.e., August 2, 2001 (copy of acknowledgement receipt postcard enclosed) and thereby requests these amendments to be effective as of August 2, 2001. Nevertheless, in order to facilitate matters, the Applicant hereby resubmits the amendments related to the drawings.

In amended Figs. 1A, 1B, 2, 3, 4A, 4B, 4C, 4D, 5A, 5B, 5C, 6A, 6B, 7A, 7B, 7C, 8, the title, subtitle and/or reference to a general figure number were deleted. In amended Fig. 9, the draft schematic was formalized.

Amendments related to the DNA and amino acid sequence (in the Specification; page 41, line 14 to page 45, line 8, and in the Sequence Listing; page 46, line 5 to page 51, line 17) are not being resubmitted herein. The Applicant therefore requests that the DNA and amino acid sequences remain in the present application

Claims 1, 2, 4, 5 and 7 remain in this application. Claims 3, 6, 8, 9 and 10 have been withdrawn as the result of an earlier restriction requirement (dated August 20, 2002).

In view of the Examiner's earlier restriction requirement, the Applicant retains the right to present claims 3, 6, 8, 9 and 10 in a divisional application.

Respectfully submitted,

BROUILLETTE KOSIE PRINCE

A handwritten signature in cursive script, appearing to read "Ronald S. Kosie".

Ronald S. Kosie

Reg. No. 28,814

1100 René-Lévesque Blvd West,

25th Floor

Montréal, Québec

Canada H3B 5C9

Telephone: (514) 397-6942

Fax: (514) 397-8515

(Docket no. 06447-010)


Appl. No. 09/725,906
Amdt dated November 20, 2003
Reply to Office Action of June 24, 2003
ANNOTATED SHEETS SHOWING CHANGES

Figure 1



~~Delivery of Rho-antagonist tissue adhesive formulation.~~

1A. ~~Application of tissue adhesive + Rho antagonist to the injured spinal cord with a pipette~~



1B. ~~Axon regeneration through the adhesion matrix + C3~~

Figure 2



~~Lesion of Corticospinal~~ ~~tract~~





Figure 3



~~Corticospinal tract lesion~~
~~(untreated adult mice)~~

Axon retraction

Lesion





~~Figure 4~~

Figure 4a




Figure 4b





Figure 4c



Figure 4d



~~Figure 5. Effect of C3/fibrin treatment on injured corticospinal tract~~



Figure 5a




Figure 5b





Figure 5c



~~Figure 6: C37 fibrin glue treated spinal cord~~

Figure 6A



Lesion




Figure 6B



~~Figure 7: Early Functional recovery~~




Figure 7A



Figure 7b





~~Delivery of G3~~







Figure 8

~~BBB tests show recovery after C3 treatment~~

~~Locomotion studies group~~






Figure 9

